Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.74 |
| ▸ | MAPK3 | P27361 | 13/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 13/20 | 0.74 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.74 |
| ▸ | CIT | O14578 | 2/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.74 |
| ▸ | STK10 | O94804 | 2/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.74 |
| ▸ | ABL1 | P00519 | 2/20 | 0.74 |
| ▸ | RAF1 | P04049 | 2/20 | 0.74 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.74 |
| ▸ | JAK1 | P23458 | 2/20 | 0.74 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.74 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.74 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.74 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.74 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.74 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.74 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 0.74 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8095240 | 0.87 | BRAF (0.74) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL13772970 | 0.87 | BRAF (0.74) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL15526774 | 0.85 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL2467603 | 0.85 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL2467604 | 0.85 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL31060883 | 0.85 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL29355995 | 0.85 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL10000524 | 0.84 | BRAF (0.83) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL16511058 | 0.83 | BRAF (0.59) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL22266371 | 0.83 | BRAF (0.66) | BRAFMAPK3MAPK1BMPR1BCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | claimed |
| CN-101282960-A | RAF inhibitor compounds and methods | GENENTECH INC (US) | 2008-10-08 | — | — | CN | claimed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | claimed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20240310266-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | BRAF 4135/4885MAPK3 1684/4885MAPK1 2257/4885 |
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 55/4885MAPK1 57/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 55/4885MAPK1 57/4885 |
| US-20240310266-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | PDCD1, PDCD1LG2, CD274 | BRAF 4/4885MAPK3 36/4885MAPK1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.